Zegfrovy Sunvozertinib drug, a quite new therapeutic agent, is generating significant buzz within the oncology community. Its mechanism of action mainly involves selective inhibition of epidermal growth factor receptor (EGFR) protein activity, showing potential in treating various neoplasm types. Preliminary clinical studies have demonstrated favor